Therapeutic Asset Ratings

Revaree Plus

Revaree Plus

Eloxatin

HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) BASED LENTIVIRAL VECTOR (LVV) PSEUDOTYPED WITH THE VESICULAR STOMATITIS VIRUS GLYCOPROTEIN G (VSV-G) ENVELOPE PROTEIN, AND ENCODING THE C11D5.3 ANTI-TNF RECEPTOR SUPERFAMILY MEMBER 17 (TNFRSF17, BCMA) SINGLE CHAIN VARIABLE FRAGMENT (SCFV) CD8/4-1BB/CD3ZETA CHIMERIC ANTIGEN RECEPTOR (CAR) UNDER THE TRANSCRIPTIONAL CONTROL OF THE MYELOPROLIFERATIVE SARCOMA VIRUS ENHANCER, NEGATIVE CONTROL REGION DELETED, DL587REV PRIMER-BINDING SITE SUBSTITUTED (MND) PROMOTE

TACROLIMUS

TACROLIMUS

FILGRASTIM

Pirtobrutinib

TACROLIMUS

(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE

Thiotepa

cc-5013

Clofarabine

Floxuridine

Fludarabine

gsk1120212

PREDNISONE TABLETS

Romidepsin

Romidepsin

Rocuronium

Zoladex

Datopotamab Deruxtecan

Tepotinib

DEXAMETHASONE

FUROSEMIDE